Principles of adoptive T cell therapy in cancer

Özcan Met; Kasper Mølgaard Jensen; Christopher Aled Chamberlain; Marco Donia; Inge Marie Svane

doi:10.1007/s00281-018-0703-z

Principles of adoptive T cell therapy in cancer

Özcan Met^*, Kasper Mølgaard Jensen, Christopher Aled Chamberlain, Marco Donia, Inge Marie Svane

^*Corresponding author for this work

Department of Clinical Medicine

35 Citations (Scopus)

Abstract

Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells or T cells genetically engineered to express tumor recognizing receptors has emerged as a powerful and potentially curative therapy for several cancers. Many ACT-based therapies have recently entered late-phase clinical testing, with several T cell therapies already achieving regulatory approval for the treatment of patients with B cell malignancies. In this review, we briefly outline the principles of adoptively transferred T cells for the treatment of cancer.

Original language	English
Journal	Seminars in Immunopathology
Volume	41
Issue number	1
Pages (from-to)	49–58
ISSN	1863-2297
DOIs	https://doi.org/10.1007/s00281-018-0703-z
Publication status	Published - 11 Jan 2019

Keywords

Adoptive cell therapy
Cancer immunotherapy
Chimeric antigen receptor
T cells
Tumor-infiltrating lymphocytes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00281-018-0703-z

Cite this

@article{e122ea5fd7c64fa2a2aac62ee58b602e,

title = "Principles of adoptive T cell therapy in cancer",

abstract = "Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells or T cells genetically engineered to express tumor recognizing receptors has emerged as a powerful and potentially curative therapy for several cancers. Many ACT-based therapies have recently entered late-phase clinical testing, with several T cell therapies already achieving regulatory approval for the treatment of patients with B cell malignancies. In this review, we briefly outline the principles of adoptively transferred T cells for the treatment of cancer.",

keywords = "Adoptive cell therapy, Cancer immunotherapy, Chimeric antigen receptor, T cells, Tumor-infiltrating lymphocytes",

author = "{\"O}zcan Met and Jensen, {Kasper M{\o}lgaard} and Chamberlain, {Christopher Aled} and Marco Donia and Svane, {Inge Marie}",

year = "2019",

month = jan,

day = "11",

doi = "10.1007/s00281-018-0703-z",

language = "English",

volume = "41",

pages = "49–58",

journal = "Seminars in Immunopathology",

issn = "1863-2297",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Principles of adoptive T cell therapy in cancer

AU - Met, Özcan

AU - Jensen, Kasper Mølgaard

AU - Chamberlain, Christopher Aled

AU - Donia, Marco

AU - Svane, Inge Marie

PY - 2019/1/11

Y1 - 2019/1/11

N2 - Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells or T cells genetically engineered to express tumor recognizing receptors has emerged as a powerful and potentially curative therapy for several cancers. Many ACT-based therapies have recently entered late-phase clinical testing, with several T cell therapies already achieving regulatory approval for the treatment of patients with B cell malignancies. In this review, we briefly outline the principles of adoptively transferred T cells for the treatment of cancer.

AB - Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells or T cells genetically engineered to express tumor recognizing receptors has emerged as a powerful and potentially curative therapy for several cancers. Many ACT-based therapies have recently entered late-phase clinical testing, with several T cell therapies already achieving regulatory approval for the treatment of patients with B cell malignancies. In this review, we briefly outline the principles of adoptively transferred T cells for the treatment of cancer.

KW - Adoptive cell therapy

KW - Cancer immunotherapy

KW - Chimeric antigen receptor

KW - T cells

KW - Tumor-infiltrating lymphocytes

U2 - 10.1007/s00281-018-0703-z

DO - 10.1007/s00281-018-0703-z

M3 - Journal article

C2 - 30187086

AN - SCOPUS:85053396565

SN - 1863-2297

VL - 41

SP - 49

EP - 58

JO - Seminars in Immunopathology

JF - Seminars in Immunopathology

IS - 1

ER -

Principles of adoptive T cell therapy in cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this